Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06345-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Yujie Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Jinling Hospital, Affiliated Hospital of Medical School, National Clinical Research Center for Kidney Diseases, Nanjing University, Nanjing, 210002, …. Hauptthemen laut MEDLINE: Immunoglobulin Light Chains, Immunoglobulin Light-chain Amyloidosis, Immunoglobulin Heavy Chains, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Medical Scientific Research Project of Jiangsu Provincial Health Commission.
Abstract (Originalsprache)
Immunoglobulin light chain (AL) amyloidosis is a rare clonal plasma cell disorder with high rate of missed diagnosis, misdiagnosis and mortality. Conventional assays, such as serum immunofixation electrophoresis (IFE) and serum free light chain (FLC) assay, are unable to accurately detect low concentrations of monoclonal protein (M protein), especially as a patient's renal function deteriorates. The heavy/light chain (HLC) assay, a relatively new method, can quantify intact immunoglobulins in serum and has proven to be valuable in the diagnosis and monitoring of multiple myeloma (MM). However, there is limited research on its application in AL amyloidosis. In this study, we evaluate the value of HLC assay in AL amyloidosis patients at different disease stages, and compare it to the performance of IFE and FLC assay. Among 40 untreated patients, 34 (85%) were positive for IFE, 34 (85%) had an abnormal free light chain ratio (FLCr), and 31 (78%) had an abnormal heavy light chain ratio (HLCr). Among 67 serum samples obtained from 44 treated patients, 57 (85%) were positive for IFE, 9 (13%) had abnormal FLCr, and 45 (67%) had abnormal HLCr. There were 1 (14%) of 7 patients in complete response (CR), 17 (68%) of 25 patients in very good partial response (VGPR), 9 (82%) of 11 patients in partial response (PR) and 6 (75%) of 8 patients in no response (NR) showed an abnormal HLCr. Our findings identified the potential value of the HLC assay in the detection of M proteins and response and serologic residual disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jinling Hospital, Affiliated Hospital of Medical School, National Clinical Research Center for Kidney Diseases, Nanjing University, Nanjing, 210002, Jiangsu, China.
- Jinling Hospital, Jinling Clinical Medical College, National Clinical Research Center for Kidney Diseases, Nanjing University of Chinese Medicine, Nanjing, China.
- Jinling Hospital, National Clinical Research Center for Kidney Diseases, Nanjing Medical University, Nanjing, China.
- Jinling Hospital, Affiliated Hospital of Medical School, National Clinical Research Center for Kidney Diseases, Nanjing University, Nanjing, 210002, Jiangsu, China. zengcaihong@nju.edu.cn.
Förderung
- National Natural Science Foundation of China
- Medical Scientific Research Project of Jiangsu Provincial Health Commission
Zitieren
APA
Wang, Y., Liu, F., Liu, Y., Dong, S., Lin, Y., Liu, X., Liang, S., Liang, D., Xu, F., Zhu, X., Yang, F., Ma, L., Yao, X., Wang, X., & Zeng, C. (2025). Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages. Annals of Hematology. https://doi.org/10.1007/s00277-025-06345-7
Vancouver
Wang Y, Liu F, Liu Y, Dong S, Lin Y, Liu X, et al. Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages. Annals of Hematology. 2025. doi:10.1007/s00277-025-06345-7
BibTeX
@article{Wang2025,
author = {Wang, Yujie and Liu, Feng and Liu, Yunyun and Dong, Shihui and Lin, Yao and Liu, Xumeng and Liang, Shaoshan and Liang, Dandan and Xu, Feng and Zhu, Xiaodong and Yang, Fan and Ma, Lei and Yao, Xinchen and Wang, Xiaoyu and Zeng, Caihong},
title = {Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06345-7}
}
EUVIMED